Kimberly L. Blackwell, MD, discusses the latest advances for patients with HER2-positive breast cancer and provides insight on the hurdles that still remain.
Suzanne L. Topalian, MD, discusses the development of PD-1/PD-L1 inhibitors, emerging biomarkers, and why a precision medicine approach is necessary to identify effective immunotherapy combination regimens.
Gabriel N. Hortobagyi, MD, discusses the MONALEESA-2 trial, in which the addition of the CDK4/6 inhibitor ribociclib to letrozole significantly improved progression-free survival in women with hormone receptor–positive advanced breast cancer.
In June, CMS selected roughly 200 medical oncology practices to participate in the public payer’s own flavor of oncology payment reform: the Oncology Care Model. This program, which launched in July, is designed to lower costs and improve quality of care for treatment episodes that start with a six-month chemotherapy regimen.
The FDA has granted a priority review designation to nivolumab as a treatment for patients with locally advanced unresectable or metastatic urothelial carcinoma following progression on a platinum-containing therapy.
Denosumab is noninferior to zoledronic acid at delaying skeletal-related events for patients with multiple myeloma.
The FDA has updated the label for enzalutamide in metastatic castration-resistant prostate cancer to include new data from the phase II TERRAIN study.
Pembrolizumab improved survival compared with chemotherapy in previously treated patients with advanced urothelial cancer in the phase III KEYNOTE-045 trial.
The latest company to suffer a public relations and stock price crisis based on its drug pricing strategy is Ariad Pharmaceuticals, which has been blasted by Sen. Bernard Sanders (I-VT) on Twitter and in a formal letter demanding justification for the price tag Ariad has attached to the chronic myelogenous leukemia drug ponatinib.